This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Teicher, B. A. Search for Related Content PubMed PubMed Citation Articles by Teicher, B. A. Related Collections Tumor Biology Tumor Biology: Model Organisms and Imaging

Reviews

Tumor models for efficacy determination

Genzyme Corporation, Framingham, Massachusetts

Requests for reprints: Beverly A. Teicher, Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701. Phone: 508-271-2843; Fax: 508-620-1203. E-mail: beverly.teicher{at}genzyme.com

The first in vivo tumor models were developed in the mid-1960s. These models were mouse leukemia models grown as ascites. The growth pattern was like that of bacteria in vivo and therefore it was possible to apply similar mathematics of growth and response to these tumors as had been worked out for bacteria. Since the development of the murine leukemia models, investigators have devoted a large effort to modeling solid tumors in mice. There are now a variety of models including syngeneic mouse tumors and human tumor xenografts grown as s.c. nodules, syngeneic mouse tumors and human tumor xenografts grown in orthotopic sites, models of disseminated disease, "labeled" tumor models that can be visualized using varied technologies, and transgenic tumor models. Each of these types of models has advantages and disadvantages to the "drug hunter" searching for improved treatments. [Mol Cancer Ther 2006;5(10):2435–43]